TY - JOUR
T1 - Investigating the cellular specificity in tumors of a surface-converting nanoparticle by multimodal imaging
AU - Fay, F.
AU - Hansen, L.
AU - Hectors, S.J.C.G.
AU - Sanchez-Gaytan, B.L.
AU - Zhao, Y.
AU - Tang, J.
AU - Munitz, J.
AU - Alaarg, A.
AU - Braza, M.S.
AU - Gianella, A.
AU - Aaronson, S.A.
AU - Reiner, T.
AU - Kjems, J.
AU - Langer, R.
AU - Hoeben, F.J.M.
AU - Janssen, H.M.
AU - Calcagno, C.
AU - Strijkers, G.J.
AU - Fayad, Z.A.
AU - Pérez-Medina, C.
AU - Mulder, W.J.M.
PY - 2017/5/17
Y1 - 2017/5/17
N2 - Active targeting of nanoparticles through surface functionalization is a common strategy to enhance tumor delivery specificity. However, active targeting strategies tend to work against long polyethylene glycol's shielding effectiveness and associated favorable pharmacokinetics. To overcome these limitations, we developed a matrix metalloproteinase-2 sensitive surface-converting polyethylene glycol coating. This coating prevents nanoparticle-cell interaction in the bloodstream, but, once exposed to matrix metalloproteinase-2, i.e., when the nanoparticles accumulate within the tumor interstitium, the converting polyethylene glycol coating is cleaved, and targeting ligands become available for binding to tumor cells. In this study, we applied a comprehensive multimodal imaging strategy involving optical, nuclear, and magnetic resonance imaging methods to evaluate this coating approach in a breast tumor mouse model. The data obtained revealed that this surface-converting coating enhances the nanoparticle's blood half-life and tumor accumulation and ultimately results in improved tumor-cell targeting. Our results show that this enzyme-specific surface-converting coating ensures a high cell-targeting specificity without compromising favorable nanoparticle pharmacokinetics.
AB - Active targeting of nanoparticles through surface functionalization is a common strategy to enhance tumor delivery specificity. However, active targeting strategies tend to work against long polyethylene glycol's shielding effectiveness and associated favorable pharmacokinetics. To overcome these limitations, we developed a matrix metalloproteinase-2 sensitive surface-converting polyethylene glycol coating. This coating prevents nanoparticle-cell interaction in the bloodstream, but, once exposed to matrix metalloproteinase-2, i.e., when the nanoparticles accumulate within the tumor interstitium, the converting polyethylene glycol coating is cleaved, and targeting ligands become available for binding to tumor cells. In this study, we applied a comprehensive multimodal imaging strategy involving optical, nuclear, and magnetic resonance imaging methods to evaluate this coating approach in a breast tumor mouse model. The data obtained revealed that this surface-converting coating enhances the nanoparticle's blood half-life and tumor accumulation and ultimately results in improved tumor-cell targeting. Our results show that this enzyme-specific surface-converting coating ensures a high cell-targeting specificity without compromising favorable nanoparticle pharmacokinetics.
UR - http://www.scopus.com/inward/record.url?scp=85019733180&partnerID=8YFLogxK
U2 - 10.1021/acs.bioconjchem.7b00086
DO - 10.1021/acs.bioconjchem.7b00086
M3 - Article
C2 - 28316241
AN - SCOPUS:85019733180
SN - 1043-1802
VL - 28
SP - 1413
EP - 1421
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
IS - 5
ER -